Synthesis and characterization of new aromatic esters based on 4,16-pregnadiene-6,20-dione skeleton by Li, Juan et al.
RESEARCH ARTICLE Open Access
Synthesis and characterization of new aromatic
esters based on 4,16-pregnadiene-6,20-dione
skeleton
Juan Li, Hongqi Li
*, Yijing Li
Abstract
A series of new aromatic esters based on 4,16-pregnadiene-6,20-dione skeleton, namely 3b-benzoyloxy-4,16-preg-
nadiene-6,20-dione and 3b-furoyloxy-4,16-pregnadiene- 6,20-dione, which may be good inhibitors for the 5a-
reductase enzyme and show high antiandrogenic activity, were synthesized starting from diosgenin. The structures
of the steroids were characterized by elemental analysis,
1H NMR,
13C NMR, IR and mass spectrum. Single crystal X-
ray diffraction measurement on one of the new compounds, 3b-(p-methoxybenzoyloxy)-4,16-pregnadiene-6,20-
dione revealed that the A, B, C, and D ring adopted half chair, distorted chair, distorted chair, and distorted envel-
ope conformation, respectively. The molecules in the crystal were packed face-to-face at the normal van der Waals
distances.
Introduction
Studies on steroids stimulated renewed interest because
apart from their estrogenic and anabolic/androgenic
activity [1-3] steroids were found to show various biolo-
gical activities including cytotoxicity [4], antiproliferative
activity [5], antimicrobial activity [6], anti-glioma activity
[7], inhibition of cholesterol a-glucosyltransferase [8],
neuromuscular blocking activity [9], differential activities
on prostate cancer cells [10], anti-osteoporosis activity
[11], and anti-aging activity [12]. Up until now steroids
have showed potential applications as 5a-reductase inhi-
bitors [13], as modulators of inflammation and immu-
nity [14], as inhibitors of 17a-hydroxylase/C17,20-lyase
[15], as predictor of tamoxifen response in premenopau-
sal breast cancer [16], as progesterone receptor antago-
nist [17], as glucocorticoid receptor imaging agents [18],
as inhibitors of protein tyrosine phosphatase 1B [19], as
reversal agents of multidrug resistance in cancer cells
[20], as inhibitors of 17b-hydroxysteroid dehydrogenase
[21], and as ligands for drug vectors [22]. Some steroidal
compounds were used for photodynamic therapy [23],
for cancer chemotherapy [24], and for DNA delivery
[25]. Moreover, cholesteric liquid crystal [26] and
steroid-based organogelator [27] were also studied.
Recently Cabeza and collegues synthesized a series of
3b-benzoyloxy-4,16-pregnadiene-6,20-dione (1a-e,
Figure 1) and 3b- cycloalkylcarbonyloxy-4,16-pregna-
diene-6,20-dione (2a-d, Figure 1) compounds starting
from 16-dehydropregnenolone acetate (16-DPA) and
evaluated their biological activities. Of these steroids 1a
is a good inhibitor for the 5a-reductase enzyme [13]
while 1b-e and 2a-d showed high antiandrogenic activ-
i t y[ 2 8 , 2 9 ] .I nc o n t i n u a t i o no fo u rs t u d yo ns t e r o i d s
[30,31] and to explore an improved way for synthesis of
new steroidal compounds from the cheap starting mate-
rial diosgenin, herein we report the synthesis and struc-
tural characterization of a series of new aromatic esters
based on 4,16-pregnadiene-6,20-dione skeleton.
Experimental
All chemical reagents were purchased from commercial
sources and used as received unless stated otherwise.
Melting points were determined on a XT-4 melting
apparatus and the quoted temperatures were uncor-
rected. Elemental analysis was carried out on an Elmen-
tar Vario EL III system.
1H NMR and
13C NMR spectra
were recorded on a Bruker AM 400 spectrometer.
CDCl3 was used as solvent and chemical shifts recorded
were internally referenced to Me4Si (0 ppm). IR spectra
were obtained on a Thermo Electron Corporation
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© 2010 Li et alNicolet 380 FT-IR spectrophotometer. Mass spectra
were recorded on a Shimadzu QP-2010 instrument
using electron impact ioniza t i o n( E I )a t7 0e V .L C - M S
spectra were obtained on an Agilent 6000 LC-MS
instrument equipped with a SunFire C18 column (4.6 ×
50 mm, 3.5 μm) under the following conditions: mobile
phase: H2O (0.05% trifluoroacetic acid (TFA)) (A)/aceto-
nitrile (0.05% TFA) (B); elution program: gradient from
5t o9 5 %o fBi n1 . 6m i na t2 . 2m l / m i n ;t e m p e r a t u r e :
50°; detection: UV (214 nm) and MS (ESI, pos mode, 70
to 1000 amu). All of the measured samples were dis-
solved in methanol. X-Ray crystal structure was mea-
sured on a Bruker Smart CCD diffractometer by using
Mo Ka radiation at 293 K.
Pseudodiosgenin diacetate (4) [32]
To a solution of diosgenin 3 (16.0 g, 38.6 mmol) and
ammonium chloride (2.5 g, 46.7 mmol) in acetic anhy-
dride (82 ml) was added pyridine (1.5 ml) and the mix-
t u r ew a sh e a t e da t1 4 0 ° Cf o r8 - 9h .T h er e s u l t i n g
solution was cooled to room temperature and poured
into ice water. The precipitate was filtered and recrystal-
lized from methanol to give the product pseudodios-
genin diacetate (4) as yellow solid (16.6 g, 86%). M.p.
70-72°C.
3b-Acetoxy-5,16-pregnadiene-20-one (5)
A solution of pseudodiosgenin diacetate (4) (15.4 g, 30.8
mmol) in acetic anhydride (76 ml) was diluted with
water (4.8 ml) and acetic acid (50 ml). The mixture was
cooled to 0°C then a solution of chromium(VI) oxide
(8.9 g, 89.0 mmol) in acetic acid (25 ml) was added
dropwise in 1 h. After the addition the solution was
allowed to warm to 10-16°C and the stirring was contin-
ued for 5 h at this temperature. Sodium bisulphite (9.3
g, 89.4 mmol) in water (30 ml) was added then the mix-
ture was refluxed for 3 h, cooled and poured into water
to give sticky solids. The crude product was crystallized
from methanol then purified by means of column chro-
matography on silica gel with petroleum ether (b.p. 60-
90°C) and ethyl acetate (4:1, v/v) as eluent to afford pro-
duct 5 (4.5 g, 41%) as yellow needles. M.p. 170-172°C
(literature [32] value: 171-172°C). Rf 0.58 (petroleum
ether/ethyl acetate, 4:1, v/v).
Compound 6 was synthesized as described in litera-
ture [33] in 90% yield and as described in literature [13]
in 95% yield. M.p. 170-172°C (literature [13] value: 170-
172°C). Rf 0.57 (petroleum ether/ethyl acetate, 4:1, v/v).
Compound 7 was synthesized as described in litera-
ture [13] in 84% yield. M.p. 243-245°C (literature [13]
value: 244-245°C). Rf 0.56 (petroleum ether/ethyl acet-
ate, 4:1, v/v).
Compound 8 was synthesized as described in litera-
ture [13] in 73% yield. M.p. 192-194°C (literature [13]
value: 193-195°C). Rf 0.58 (petroleum ether/ethyl acet-
ate, 4:1, v/v).
3b-Hydroxypregna-4,16-diene-6,20-dione (9)
As o l u t i o no fs t e r o i d8 (0.3 g, 0.8 mmol) in methanol
(45 ml) and 2% aqueous sodium hydroxide (3 ml) was
stirred for 30 min at room temperature. The resulting
solution was poured into ice water (45 ml) then
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Figure 1 Chemical structure of compound 1a-e and 2a-d.
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Page 2 of 8extracted with ethyl acetate (3 × 30 ml). The organic
phase was dried over anhydrous magnesium sulfate and
the solvent was removed in vacuum. The residue was
purified by column chromatography on silica gel with
petroleum ether and ethyl acetate (1:1, v/v) as eluent to
afford product 9 (0.25 g, 74%) as pale yellow needles. M.
p. 168-170°C (literature [13] value: 168-170°C). Rf 0.52
(petroleum ether/ethyl acetate, 4:1, v/v).
3b-(p-Methoxybenzoyloxy)pregna-4,16-diene-6,20-dione
(10a)
A solution containing steroid 9 (0.10 g, 0.3 mmol), p-
methoxybenzoic acid (0.13 g, 0.7 mmol), 1,3-dicyclohex-
ylcarbodiimide (DCC, 0.10 g, 0.5 mmol) and 4-dimethy-
laminopyridine (DMAP, 0.06 g, 0.5 mmol) in methylene
dichloride (6 ml) was stirred for 2 h at about 10°C. Ice
water was added and the reaction mixture was extracted
with chloroform (3 × 20 ml). The organic phase was
dried over anhydrous magnesium sulfate and the solvent
was removed in vacuum. The crude product was dis-
solved in ethyl acetate and filtered through a column
containing silica gel. The organic solvent was removed
in vacuum to give a white crystalline solid 10a (0.14 g,
71%). M.p. 244-246°C. Rf 0.50 (petroleum ether/ethyl
acetate, 4:1, v/v).
1HN M R( C D C l 3): 0.94 (s, 3 H, H-C
(18)); 1.10 (s, 3 H, H-C(19)); 2.28 (s, 3 H, H-C(21)); 3.87
(s, 3 H, OMe); 5.56 (m, 1 H, H-C(3)); 6.23 (m, 1 H, H-C
(4)); 6.71 (t, 1 H, J = 1.3 Hz, H-C(16)); 6.93 (m, 2 H, H-
Ph); 8.02 (m, 2 H, H-Ph).
13CN M R( C D C l 3): 15.8 (C
(18)); 19.7 (C(19)); 27.1 (C(21)); 69.5 (C(3)); 131.8 (C
(4)); 143.8 (C(16)); 147.9 (C(5)); 154.9 (C(17)); 165.9
(ester C = O); 196.6 (C(20)); 201.9 (C(6)). IR (KBr):
3075, 2958, 1706, 1690, 1656, 1629. EI-MS: 312 (12, M
+
+1-p-MeO-C6H4COO), 175 (31), 157 (38), 121 (30),
105 (41), 93 (33), 91 (66), 79 (51), 77 (46), 43 (100). LC-
MS: 485.4 (M
+ + Na, retention time 2.20 min). Anal.
Calcd. for C29H34O5:C ,7 5 . 3 0 ;H ,7 . 4 1 ;F o u n d :C ,7 5 . 1 2 ;
H, 7.37.
Other steroidal compounds 10b-j were prepared in a
similar procedure and the physical data of the new ster-
oids were as follows.
3b-(o-Methoxybenzoyloxy)pregna-4,16-diene-6,20-dione
(10b)
White powder. Yield 45%. M.p. 240-242°C. Rf 0.42 (pet-
roleum ether/ethyl acetate, 4:1, v/v).
1HN M R( C D C l 3):
0.93 (s, 3 H, H-C(18)); 1.07 (s, 3 H, H-C(19)); 2.27 (s, 3
H, H-C(21)); 3.89 (s, 3 H, OMe); 5.56 (m, 1 H, H-C(3));
6.23 (m, 1 H, H-C(4)); 6.73 (t, J = 1.6 Hz, H-C(16)); 6.96
(m, 2 H, H-Ph); 7.46 (m, 1 H, H-Ph); 7.80 (m, 1 H, H-
Ph).
13CN M R( C D C l 3): 17.5 (C(18)); 22.0 (C(19)); 26.5
(C(21)); 71.8 (C(3)); 136.0 (C(4) and C(16)); 146.1 (C(5));
149.9 (C(17)); 167.0 (ester C = O); 198.9 (C(20)); 203.8
(C(6)). IR (KBr): 3040, 2946, 1688. LC-MS: 485.4 (M
+ +
Na, retention time 2.13 min). Anal. Calcd. for C29H34O5:
C, 75.30; H, 7.41; Found: C, 75.04; H, 7.46.
3b-(o-Methylbenzoyloxy)pregna-4,16-diene-6,20-dione
(10c)
White powder. Yield 62%. M.p. 182-184°C. Rf 0.39 (pet-
roleum ether/ethyl acetate, 3:1, v/v).
1HN M R( C D C l 3):
0.94 (s, 3 H, H-C(18)); 1.08 (s, 3 H, H-C(19)); 2.28 (s, 3
H, H-C(21)); 2.60 (s, 3 H, Me-Ph); 5.56 (m, 1 H, H-C
(3)); 6.24 (m, 1 H, H-C(4)); 6.72 (t, 1 H, J = 1.8 Hz, H-C
(16)); 7.23 (m, 2 H, H-Ph); 7.40 (m, 1 H, H-Ph); 7.93
(m, 1 H, H-Ph).
13C NMR (CDCl3): 15.8 (C(18)); 19.7 (C
(19)); 27.1 (C(21)); 69.6 (C(3)); 132.1 (C(4)); 143.9 (C
(16)); 148.0 (C(5)); 154.9 (C(17)); 168.4 (ester C = O);
196.7 (C(20)); 201.8 (C(6)). IR (KBr): 3070, 2946, 1688.
LC-MS: 469.4 (M
+ + Na, retention time 2.28 min). Anal.
Calcd. for C29H34O4:C ,7 8 . 0 0 ;H ,7 . 6 7 ;F o u n d :C ,7 7 . 8 1 ;
H, 7.63.
3b-(m-Methylbenzoyloxy)pregna-4,16-diene-6,20-dione
(10d)
White powder. Yield 69%. M.p. 138-140°C. Rf 0.42 (pet-
roleum ether/ethyl acetate, 3:1, v/v).
1HN M R( C D C l 3):
0.95 (s, 3 H, H-C(18)); 1.11 (s, 3 H, H-C(19)); 2.27 (s, 3
H, H-C(21)); 5.60 (m, 1 H, H-C(3)); 6.24 (m, 1 H, H-C
(4)); 6.71 (t, 1 H, J = 1.8 Hz, H-C(16)); 7.32 (m, 2 H, H-
Ph); 7.44 (m, 1 H, H-Ph); 7.84 (m, 1 H, H-Ph).
13C
NMR (CDCl3): 15.8 (C(18)); 19.7 (C(19)); 27.1 (C(21));
69.8 (C(3)); 138.0 (C(4)); 143.9 (C(16)); 148.0 (C(5));
154.9 (C(17)); 166.4 (ester C = O); 196.6 (C(20)); 201.9
(C(6)). IR (KBr): 3060, 2945, 1688, 1589, 1457. LC-MS:
469.4 (M
+ + Na, retention time 2.29 min). Anal. Calcd.
for C29H34O4: C, 78.00; H, 7.67; Found: C, 78.18; H,
7.71.
3b-(p-Nitrobenzoyloxy)pregna-4,16-diene-6,20-dione (10e)
Pale yellow powder. Yield 46%. M.p. 174-176°C. Rf 0.36
(petroleum ether/ethyl acetate, 3:1, v/v).
1HN M R
(CDCl3): 0.95 (s, 3 H, H-C(18)); 1.12 (s, 3 H, H-C(19));
2.28 (s, 3 H, H-C(21)); 5.62 (m, 1 H, H-C(3)); 6.21 (m, 1
H, H-C(4)); 6.72 (t, 1 H, J = 1.8 Hz, H-C(16)); 8.23 (m,
2H ,H - P h ) ;8 . 2 8( m ,2H ,H - P h ) .
13CN M R( C D C l 3):
15.8 (C(18)); 19.6 (C(19)); 27.1 (C(21)); 71.0 (C(3));
130.8 (C(4)); 135.4 (C(16)); 148.6 (C(5)); 154.9 (C(17));
164.3 (ester C = O); 196.6 (C(20)); 201.8 (C(6)). IR
(KBr): 3062, 2946, 1688, 1528, 1456. LC-MS: 500.3 (M
+
+ Na, retention time 2.17 min). Anal. Calcd. for
C28H31NO6: C, 70.42; H, 6.54; N, 2.93; Found: C, 70.57;
H, 6.52; N, 2.87.
3b-(o-Nitrobenzoyloxy)pregna-4,16-diene-6,20-dione (10f)
Pale yellow powder. Yield 55%. M.p. 158-161°C. Rf 0.29
(petroleum ether/ethyl acetate, 3:1, v/v).
1HN M R
(CDCl3): 0.92 (s, 3 H, H-C(18)); 1.05 (s, 3 H, H-C(19));
Li et al. Chemistry Central Journal 2010, 4:18
http://journal.chemistrycentral.com/content/4/1/18
Page 3 of 82.27 (s, 3 H, H-C(21)); 5.60 (m, 1 H, H-C(3)); 6.17 (m, 1
H, H-C(4)); 6.70 (t, 1 H, J = 1.8 Hz, H-C(16)); 7.63-7.68
(m, 2 H, H-Ph); 7.72 (m, 1 H, H-Ph); 7.95 (m, 1 H, H-
Ph).
13CN M R( C D C l 3): 15.8 (C(18)); 19.6 (C(19)); 27.1
(C(21)); 71.5 (C(3)); 133.0 (C(4)); 143.8 (C(16)); 148.6 (C
(5)); 154.9 (C(17)); 165.1 (ester C = O); 196.6 (C(20));
201.6 (C(6)). IR (KBr): 3033, 2945, 1732, 1687, 1656,
1628, 1587, 1540, 1456. LC-MS: 500.3 (M
+ +N a ,
retention time 2.11 min). Anal. Calcd. for C28H31NO6:
C, 70.42; H, 6.54; N, 2.93; Found: C, 70.25; H, 6.49; N,
2.90.
3b-(m-Nitrobenzoyloxy)pregna-4,16-diene-6,20-dione
(10g)
Pale yellow powder. Yield 47%. M.p. 176-178°C. Rf 0.38
(petroleum ether/ethyl acetate, 3:1, v/v).
1HN M R
O
O
HO
O
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OAc
3 4
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Figure 2 Synthetic route of target steroids 10a-j.
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Page 4 of 8(CDCl3): 0.94 (s, 3 H, H-C(18)); 1.12 (s, 3 H, H-C(19));
2.27 (s, 3 H, H-C(21)); 5.63 (m, 1 H, H-C(3)); 6.20 (m, 1
H, H-C(4)); 6.71 (t, J = 1.2 Hz, H-C(16)); 7.66 (m, 1 H,
H - P h ) ;8 . 3 6 - 8 . 4 3( m ,2H ,H - P h ) ;8 . 8 6( m ,1H ,H - P h ) .
13CN M R( C D C l 3): 15.8 (C(18)); 19.6 (C(19)); 27.1 (C
(21)); 71.0 (C(3)); 135.4 (C(4)); 143.8 (C(16)); 148.6 (C
(5)); 154.9 (C(17)); 164.1 (ester C = O); 196.6 (C(20));
201.7 (C(6)). IR (KBr): 3040, 2945, 1689, 1526, 1456.
LC-MS: 500.3 (M
+ + Na, retention time 2.17 min). Anal.
Calcd. for C28H31NO6: C, 70.42; H, 6.54; N, 2.93; Found:
C, 70.27; H, 6.58; N, 2.88.
3b-(3,5-Dinitrobenzoyloxy)pregna-4,16-diene-6,20-dione
(10h)
Pale yellow powder. Yield 45%. M.p. 168-170°C. Rf 0.59
(petroleum ether/ethyl acetate, 2:1, v/v).
1HN M R
(CDCl3): 0.95 (s, 3 H, H-C(18)); 1.15 (s, 3 H, H-C(19));
2.29 (s, 3 H, H-C(21)); 5.70 (m, 1 H, H-C(3)); 6.20 (m, 1
H, H-C(4)); 6.72 (t, 1 H, J = 1.4 Hz, H-C(16)); 9.16 (m,
2H ,H - P h ) ;9 . 2 4( m ,1H ,H - P h ) .
13CN M R( C D C l 3):
15.8 (C(18)); 19.5 (C(19)); 27.1 (C(21)); 72.2 (C(3));
133.8 (C(4)); 143.8 (C(16)); 148.6 (C(5)); 154.8 (C(17));
162.2 (ester C = O); 196.6 (C(20)); 201.6 (C(6)). IR
(KBr): 3037, 2946, 1689, 1543, 1457. LC-MS: 500.3 (M
+
+ Na, retention time 3.14 min). Anal. Calcd. for
C28H30N2O8: C, 64.36; H, 5.79; N, 5.36; Found: C, 64.22;
H, 5.75; N, 5.19.
3b-(o-Chlorobenzoyloxy)pregna-4,16-diene-6,20-dione
(10i)
White powder. Yield 64%. M.p. 192-194°C. Rf 0.32 (pet-
roleum ether/ethyl acetate, 3:1, v/v).
1HN M R( C D C l 3):
0.95 (s, 3 H, H-C(18)); 1.11 (s, 3 H, H-C(19)); 2.27 (s, 3
H, H-C(21)); 5.59 (m, 1 H, H-C(3)); 6.24 (m, 1 H, H-C
(4)); 6.71 (t, 1 H, J = 1.8 Hz, H-C(16)); 7.32 (m, 1 H, H-
Ph); 7.36 (m, 2 H, H-Ph); 7.87 (m, 1 H, H-Ph).
13C
NMR (CDCl3): 15.8 (C(18)); 19.6 (C(19)); 27.1 (C(21));
70.5 (C(3)); 133.9 (C(4)); 143.8 (C(16)); 148.2 (C(5));
154.9 (C(17)); 165.2 (ester C = O); 196.6 (C(20)); 201.7
(C(6)). IR (KBr): 3040, 2946, 1688, 1522, 1456. LC-MS:
490.2 (M
+ + Na, retention time 2.23 min). Anal. Calcd.
for C28H31ClO4:C ,7 2 . 0 1 ;H ,6 . 6 9 ;F o u n d :C ,7 1 . 8 3 ;H ,
6.65.
3b-(2-Furoyloxy)pregna-4,16-diene-6,20-dione (10j)
White powder. Yield 77%. M.p. 180-182°C. Rf 0.40 (pet-
roleum ether/ethyl acetate, 2:1, v/v).
1HN M R( C D C l 3):
0.94 (s, 3 H, H-C(18)); 1.09 (s, 3 H, H-C(19)); 2.28 (s, 3
H, H-C(21)); 5.57 (m, 1 H, H-C(3)); 6.20 (m, 1 H, H-C
(4)); 6.52 (t, 1 H, J = 1.8 Hz, H-C(16)); 6.71 (m, 1 H, H-
Ar); 7.20 (m, 1 H, H-Ar); 7.59 (m, 1 H, H-Ar).
13C
NMR (CDCl3): 15.8 (C(18)); 19.6 (C(19)); 27.1 (C(21));
69.9 (C(3)); 128.7 (C(4)); 143.8 (C(16)); 148.1 (C(5));
154.8 (C(17)); 158.3 (ester C = O); 196.6 (C(20)); 201.8
(C(6)). IR (KBr): 3042, 2946, 1720, 1689, 1657, 1580,
1523, 1457. LC-MS: 445.2 (M
+ +N a ,r e t e n t i o nt i m e
2.06 min). Anal. Calcd. for C26H30O5:C ,7 3 . 9 1 ;H ,7 . 1 6 ;
Found: C, 73.73; H, 7.21.
Results and Discussion
The synthetic route of the target steroids 3b-benzoylox-
ypregna-4,16-diene-6,20-dione (10a-i) and 3b-furoyloxy-
pregna-4,16-diene-6,20-dione (10j)w a ss h o w e di n
Figure 2. At first the starting material diosgenin was
transformed by acetylation and oxidation to 3b-acetoxy-
5,16-pregnadiene-20-one (16-DPA, 5). The transforma-
tion could be achieved stepwise or in a one-pot reaction
[32]. We adopted the former in consideration that the
purification of the product was easier to yield 16-DPA
of higher purity. Epoxidation of 16-DPA to form steroid
6 was conducted by using 30% H2O2/HCO2H[ 3 3 ]o r
m-chloroperoxybenzoic acid (m-CPBA) [13] oxidation
system in 90% or 95% yield.
Conversion of compound 6 to 7 was carried out in a
similar way as reported in literature [13] and the yield
of steroid 7 w a si m p r o v e df r o m8 1 %t o8 4 % .D e h y d r a -
tion of 7 with thionyl chloride in pyridine resulted com-
pound 8. We found that the quality of the solvent
pyridine had an effect on the yield of the steroid 8.
When dried pyridine (refluxed in the presence of potas-
sium hydroxide for 2 h before distillation) was used
instead of pyridine of analytically pure grade without
treatment, the yield of 8 was improved to 73% from the
literature [13] value 66%. Compound 8 was hydrolyzed
with aqueous sodium hydroxide in methanol to afford
3b-hydroxypregna-4,16-diene-6,20-dione (9). The proce-
dure for workup was improved by using extraction (with
Table 1 Characteristic chemical shifts in
1H NMR spectra
of steroids 10a-j
δ (ppm)
No. H-C
(18)
H-C
(19)
H-C
(21)
H-C
(3)
H-C
(4)
H-C
(16)
H-Ar
10a 0.94 1.10 2.28 5.56 6.23 6.71 6.93, 8.02
10b 0.93 1.07 2.27 5.56 6.23 6.73 6.96, 7.46, 7.80
10c 0.94 1.08 2.28 5.56 6.24 6.72 7.23, 7.40, 7.93
10d 0.95 1.11 2.27 5.60 6.24 6.71 7.30-7.38, 7.84-
7.87
10e 0.95 1.12 2.28 5.62 6.21 6.72 8.22-8.24, 8.28-
8.31
10f 0.92 1.05 2.27 5.60 6.17 6.70 7.63-7.68, 7.72,
7.95
10g 0.94 1.12 2.27 5.63 6.20 6.71 7.66, 8.36-8.43,
8.86
10h 0.95 1.15 2.29 5.70 6.20 6.72 9.16, 9.24
10i 0.95 1.11 2.27 5.59 6.24 6.71 7.32, 7.44, 7.86
10j 0.94 1.09 2.28 5.57 6.20 6.52 6.71, 7.20, 7.59
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Page 5 of 8ethyl acetate) and concentration replacing filtration and
subsequent recrystallization and pure product 9 was
obtained in 74% yield, significantly higher than the lit-
erature [13] value 60%.
The target steroids 3b-benzoyloxypregna-4,16-diene-
6,20-dione (10a-i)a n d3 b- furoyloxypregna-4,16-diene-
6,20-dione (10j) were synthesized through Steglich reac-
tion from 9, substituted benzoic acid or furoic acid, and
DCC catalyzed by DMAP in fair to good yields (45%-
77%), depending upon the structure of the aryl acids. It
seems that the steric hindrance from the aryl acid struc-
ture leads to decrease in the yield. Therefore the highest
yield of the Steglich reaction came from furoic acid
(77%) while the reactions with dinitrobenzoic acid or
nitrobenzoic acid gave the lowest yield.
The chemical structures of steroids 10a-j were fully
characterized by elemental analysis,
1H NMR,
13C NMR,
IR and mass spectrum and melting point measurements.
Characteristic chemical shifts in
1H NMR spectra of
steroids 10a-j were summarized in Table 1. All the che-
mical shifts of protons in methyl groups, OCH moieties,
C = CH moieties, and aryl rings were in the reasonable
range and the spectra data were in good accordance
with the structures.
Single crystals of 10a suitable for X-ray crystal diffrac-
tion measurement were obtained by slow evaporation of
a solution of 10a in 1:1 petroleum ether and ethyl acet-
ate. X-Ray data for crystals of 10a were collected by gra-
phite-monochromatized Mo Ka radiation at 293 K and
the crystal data and experimental details for compound
10a were summarized in Table 2. The structure was
solved by direct methods and refined by full-matrix
least-squares with anisotropic temperature factors for
the non-hydrogen atoms. The hydrogen atoms bonded
to the carbon atoms were assigned based on the
expected bonding geometry. The hydrogen atoms were
refined isotropically in the final least-squares cycles.
The crystal structure and molecular packing of steroid
10a were shown in Figure 3 and Figure 4 respectively. It
can be seen that the molecule consists of three six-
membered rings (A, B, and C ring) and one five-mem-
bered ring (D ring), all trans fused. The six-membered
rings A, B, and C occur in a half chair, distorted chair,
and distorted chair conformation, respectively. Ring D
adopts a distorted envelope conformation. The mole-
cules in the crystal were packed face-to-face at the
Table 2 Crystal data and experimental details for
compound 10a
Empirical formula C29 H34 O5
Formula weight 462.56
Temperature 296(2) K
Wavelength 0.71073 Å
Crystal system, space group Monoclinic, P2(1)
Unit cell dimensions a = 10.9972(10) Å a = 90°
b = 7.4244(7) Å b = 108.7520(10)°
c = 15.8025(15) Å g = 90°
Volume 1221.7(2) Å
3
Z, Calculated density 2, 1.257 Mg/m
3
Absorption coefficient 0.085 mm
-1
F(000) 496
Crystal size 0.12 × 0.10 × 0.08 mm
θ range for data collection 2.72 <θ < 24.99°
Reflections collected/unique 10638/4269 [R (int) = 0.0219]
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 0.9933 and 0.9899
Refinement method Full-matrix least-squares on F
2
Data/restraints/parameters 4269/1/311
Goodness-of-fit on F
2 0.999
Final R indices [I > 2s (I)] R1 = 0.0377, wR2 = 0.0884
R indices (all data) R1 = 0.0492, wR2 = 0.0958
Absolute structure parameter 0.1(11)
Largest diff. peak and hole 0.167 and –0.140 eÅ
-3
Figure 3 Crystal structure of compound 10a.
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Page 6 of 8normal van der Waals distances, similar to the crystal
structure of 3b-(p-fluorobenzoyloxy)-4,16-pregnadiene-
6,20-dione [34]. CCDC-787721 contains the supplemen-
tary crystallographic data for this paper. These data can
be obtained free of charge via http://www.ccdc.cam.ac.
uk/data_request/cif.
Conclusions
In summary, ten new aromatic esters based on 4,16-preg-
nadiene-6,20-dione skeleton, namely 3b-benzoyloxy-4,16-
pregnadiene-6,20-dione and 3b-furoyloxy-4,16-pregna-
diene-6,20- dione were synthesized starting from dios-
genin. The structures of the steroids were characterized by
elemental analysis,
1HN M R ,
13C NMR, IR and mass spec-
trum. Single crystal X-ray diffraction measurement on one
of the new compounds, 3b-(p-methoxybenzoyloxy)-4,16-
pregnadiene-6,20-dione revealed that the A, B, C, and D
ring adopted half chair, distorted chair, distorted chair,
and distorted envelope conformation, respectively. The
molecules in the crystal were packed face-to-face at the
normal van der Waals distances. These new steroids may
show high antiandrogenic activity and serve as good inhi-
bitors for the 5a-reductase enzyme. Investigation of the
inhibitory activity of the new steroids for the 5a-reductase
enzyme will be conducted in the near future.
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